PROFESSIONAL EDITION

The largest community of pharma leaders

U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer

PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BMS–U.S. FDA Accepts for Priority Review Application for Opdivo as Adjuvant Therapy for Patients w/Resected Esophageal or Gastroesophageal Junction Cancer

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles